Skip to content
Stock screener

NTRA Natera, Inc. stock chart & analysis

Conviction 36HealthcareScan · Fri, Nov 6, 2026

Natera, Inc. (NTRA) closed at $310.67 (-14.59%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 29, RS Rating 93, -28.9% from its 52-week high, +35.7% year to date. Sector: Healthcare · Services-Medical Laboratories.

NTRA$310.67-14.59%
ResistanceSupportVol 14Insider sellCongress buyCongress sell
Loading chart…
Natera, Inc.Services-Medical Laboratorieswww.natera.com ↗
Price310.67
Change-14.59%
Gap-12.17%
Rel volume4.38×
Avg volume2.03M
Avg $ vol776.32M
SMA 20396.70
SMA 50380.25
SMA 200269.35
Price vs 50-18.27%
Price vs 200+15.38%
MA stackmixed
50/200 cross—
Supertrenddown · 394.93
RSI (14)29
MACD hist-10.39
MACD crossbear · 5d
Stoch %K / %D5 / 16
ADX (14)30
+DI / −DI12 / 38
RSI divergence—
MACD divergence—
ATR %7.68%
ADR %5.04%
52w high437.41
52w low181.00
From 52w high-28.95%
Above 52w low+71.70%
New 52w highNo
SqueezeOff
Bollinger width25.00%
%B-0.37
Donchian pos5.12%
Donchian high436.19
Donchian low304.01
AVWAP (52w high)385.17
vs AVWAP high-19.31%
AVWAP (52w low)292.46
vs AVWAP low+6.26%
OBV trendFlat
Chaikin MF (20)-0.07
Today vs 20d4.38×
Avg vol (14d)2.39M
Avg vol (20d)2.03M
Avg $ vol (20d)776.32M
Market cap45.06B
RS Rating93 / 99
RS 3m (vs SPY)+2.49%
RS 6m (vs SPY)+60.30%
RS line new highNo
Trend template6/8
Technical rank62.6
1 week-24.99%
1 month-20.47%
3 months-2.38%
6 months+60.00%
1 year+55.45%
YTD+35.66%
P/E-216.49
P/B24.10
P/S19.54
P/FCF413.01
EPS-1.52
Div yield—
ROE-11.13%
ROA-7.57%
Debt/Eq0.19
Current2.81
EV/EBITDA-165.32
Gross margin—
Net margin-9.03%
Rev growth35.90%
EPS growth-9.31%
Price target412.08
Target upside32.60%
Analyst ratingBuy
Institutional103.83%
Ent. value44.33B
Revenue793.98M
Net income-59.91M
Gross profit—
Free cash flow109.11M
IndustryServices-Medical Laboratories
ExchangeNasdaq
Shares out143.22M
Employees6.14K
ListedThu, Jul 2, 2015
Free float132.15M
Float %95.5%
Short interest—
Days to cover—
Short volume27.1%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est−$0.39 vs −$0.17
Last surprise-129.4% miss
Setup gradeD
Conviction36 / 100
Pattern quality—
Tech rank62.6 / 100
Group rank23 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance436.80
Support382.39
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

NTRA technical analysis

Trend

NTRA's moving averages are mixed — no clean uptrend or downtrend. It closed 18.3% below the 50-day ($380.25) and 15.4% above the 200-day ($269.35). ADX(14) at 30 points to a strong, established trend. It meets 6 of 8 trend-template criteria.

Momentum

RSI(14) is 29, in oversold territory. MACD crossed below its signal line 5 sessions ago. Its RS Rating of 93 puts its weighted 12-month performance ahead of about 93% of the US market.

Volume and volatility

Volume on the latest session ran 4.4× its 20-day average. It trades about $776.3M a day on average. ATR(14) is $23.87, 7.7% of price — its typical daily range. Chaikin Money Flow (-0.07) shows distribution.

Key levels

The chart pattern's support is $382.39 and its resistance $436.80. The 52-week range is $181.00 to $437.41; price is 28.9% below the high and 71.7% above the low. The VWAP anchored at the 52-week high is $385.17, above price.

Performance

NTRA returned -25.0% (1 week), -20.5% (1 month), -2.4% (3 months), +60.0% (6 months), +55.5% (1 year), +35.7% (year to date).

About Natera, Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Services-Medical Laboratories · Listed 2015 · 6,140 employees

Recent news

Congress activity

Disclosed STOCK Act trades in NTRA · 4 recent

All disclosures →
MemberSideAmount
Josh Gottheimer
Josh Gottheimer
house · D · NJ · traded 2025-09-22
Buy$1K–$15K
Josh Gottheimer
Josh Gottheimer
house · D · NJ · traded 2025-08-22
Buy$1K–$15K
Josh Gottheimer
Josh Gottheimer
house · D · NJ · traded 2025-07-22
Sell$1K–$15K
Josh Gottheimer
Josh Gottheimer
house · NJ · traded 2024-11-20
Buy$1K–$15K

Insider activity

SEC Form 4 transactions in NTRA · open-market 10 sells

InsiderSideShares
Brophy Michael Burkes
CHIEF FINANCIAL OFFICER · Common Stock · 2026-11-03
Sell470
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS · Common Stock · 2026-11-02
Sell9
Brophy Michael Burkes
CHIEF FINANCIAL OFFICER · Common Stock · 2026-11-02
Sell8
Brophy Michael Burkes
CHIEF FINANCIAL OFFICER · Common Stock · 2026-11-02
Sell317
Chapman Steven Leonard
CEO AND PRESIDENT · Common Stock · 2026-11-02
Sell21
Chapman Steven Leonard
CEO AND PRESIDENT · Common Stock · 2026-11-02
Sell914
Chapman Steven Leonard
CEO AND PRESIDENT · Common Stock · 2026-11-02
Sell2.87K
Fesko John
PRESIDENT, CHIEF BUS. OFFICER · Common Stock · 2026-11-02
Sell7
Fesko John
PRESIDENT, CHIEF BUS. OFFICER · Common Stock · 2026-11-02
Sell295
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS · Common Stock · 2026-11-02
Sell410

SEC filings

EDGAR filings in NTRA · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.